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Background: Among hospitalized patients, indications for the measurement of magnesium levels and treatment of
hypomagnesemia with intravenous magnesium are not well defined. Recently, there have been reports of
worldwide shortages of intravenous magnesium sulphate.
Objective: To examine secular trends in the administration of intravenous magnesium on hospital wards at a
tertiary care institution. The secondary objective is to identify factors associated with magnesium use among
admitted patients.
Methods: Retrospective cross-section review of hospitalized patients at a single Canadian tertiary care center.
Utilization of non-parental nutrition intravenous magnesium from 2003 to 2013 stratified by hospital ward was
examined. In addition, patient level data from select wards (including medical and surgical services) was examined
at early and more recent time period (4/2006 versus 4/2013).
Results: Among the 248,329 hospitalized patients, intravenous magnesium use increased by 2.86 fold from 2003 to
2013. Not all wards had an increase whereas some had nearly a 10 fold increase in use. In the sample (n = 769),
(adjusting for admission magnesium level, presence of an indication for intravenous magnesium, ward location,
comorbidity and demographics) intravenous magnesium administration was higher (25.8 % versus 5.5 %) in 2013
versus 2006 (OR 13.91 (95 % CI, 6.21-31.17, p < 0.001). Despite this increase in intravenous magnesium
administration, <3 % of patients were admitted on oral magnesium in 2006 and 2013. For patients receiving
intravenous magnesium only a minority were discharged on oral therapy despite low levels.
Conclusions: This center has witnessed a considerable increase in the use of in-hospital intravenous magnesium
over the last 6 years that cannot be explained for by medical indications. The risks and benefits of this therapy
deserve further study. If this change in practice is representative of other North American hospitals, it may be
responsible for recent drug shortages.
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Contexte: Les indications concernant la mesure des niveaux sanguins de magnésium et le traitement de
l’hypomagnésémie par infusion intraveineuse de magnésium chez les patients hospitalisés sont mal définies. On a
récemment rapporté des pénuries à l’échelle mondiale de sulfate de magnésium destiné à l’infusion intraveineuse.
Objectifs: D’une part, examiner les tendances séculaires en matière d’administration de magnésium par voie
intraveineuse dans divers services hospitaliers d’un centre de soins tertiaires. D’autre part, déterminer les facteurs
associés à l’utilisation du magnésium chez les patients hospitalisés.
Méthodes: Étude transversale et rétrospective auprès des patients hospitalisés dans un seul centre canadien de
soins tertiaire. On a étudié un échantillon qui témoigne du recours à l’administration intraveineuse de magnésium,
de 2003 à 2013, en stratifiant par service hospitalier.
Résultats: Chez les 248 329 patients hospitalisés, le recours à l’infusion de magnésium par voie intraveineuse a
augmenté de 2,86 fois entre 2003 et 2013. Dans certains services, aucune augmentation n’a été notée alors que
dans d’autres, l’utilisation a augmenté de près de 10 fois. Dans l’échantillon (n = 769), (ajusté selon le taux de
magnésium administré, la présence d’une indication nécessitant une infusion de magnésium, l’emplacement des
services, la comorbidité et les données démographiques), l’administration de magnésium par voie intraveineuse
était plus fréquente (25,8 % par rapport à 5,5 %) en 2013 qu’en 2006 (RIA = 13,91 (IC, 95 %, 6,21-31,17, p < 0,001).
Malgré cette augmentation de l’utilisation du magnésium par voie intraveineuse, <3 % des patients avaient été
admis pour administration orale de magnésium en 2006 et en 2013. Parmi les patients qui ne recevaient le
magnésium que par voie intraveineuse, seule une minorité avait reçu son congé avec une thérapie par voie orale,
en dépit des faibles taux.
Conclusion: Nous avons observé une augmentation considérable dans l’utilisation de l’infusion de magnésium par
voie intraveineuse en milieu hospitalier au cours des 6 dernières années, ce qui n’est pas justifié par des indications
d’ordre médical. Les avantages et les risques que comporte cette thérapie méritent une étude approfondie. Ce
changement de pratique, s’il s’observe dans d’autres hôpitaux nord-américains, pourrait expliquer les récentes
pénuries de médicaments.What was known before
There have been recent shortages of magnesium
sulphate for intravenous use in North America from
increased demand. The reasons for this increase in
utilization are unclear given the lack of evidence for its
use in clinical randomized trials outside of the preven-
tion of pre-eclampsia.
What this adds
Intravenous magnesium sulphate use has increased
nearly 3 fold in this tertiary Canadian hospital. The in-
crease cannot be explained by patient characteristics
and likely represents a change in practice. Few patients
were discharged on oral magnesium supplements des-
pite low levels at discharge and follow up. Evidence
based guidelines for the measurement and treatment
of low magnesium are needed.
Background
Magnesium is an essential nutrient for humans. Mag-
nesium is the second most abundant intracellular cat-
ion and is a cofactor for many enzymes that are
required for healthy cell function. Profound deficiency
is associated with weakness, tetanus and cardiac ar-
rhythmias [1, 2]. The prevalence of hypomagnesaemiais variable and depends on the laboratory definition of a
low normal level. In hospitalized patients, as high as
10-15 % have hypomagnesaemia and this increases
to >50 % in intensive care units [1].
Hypomagnesemia has been associated with several ad-
verse outcomes and medical conditions. Low total mag-
nesium levels among intensive care unit patients are
associated with higher rates of mortality [3–5]. Hypo-
magnesaemia and low magnesium intake by dietary re-
call are associated with diabetes mellitus, cardiovascular
disease including stroke in some but not all community
based cohort studies [6–9]. While hypomagnesemia may
be associated with poor outcomes, the benefits of cor-
recting hypomagnesemia are not clear in all conditions.
In some but not all studies, magnesium supplementation
is associated with improved blood pressure, lipid and
glucose control [2, 10–12]. There is evidence that thera-
peutic doses of magnesium might improve blood flow
and reduce reperfusion injury [13]. Intravenous magne-
sium is very effective in pre-eclampsia [14]. Intravenous
magnesium is helpful in some patients with ventricular
arrhythmias [13]. There are also a large number of ran-
domized controlled studies examining the role of intra-
venous magnesium administration to improve outcomes
associated with myocardial infarction, atrial fibrillation,
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the treatment of acute asthma [15–19]. However, several
of the meta-analyses and systematic reviews of these tri-
als have been contradictory or suggest that alternative
therapies are superior [20–22].
In 2011 [23], there were world-wide shortages of many
generic medications, leading President Obama to charge
the Federal Drug Administration with ensuring adequate
supply of important medications for the US population.
Intravenous magnesium sulphate was cited as one of the
medications being in short supply [24]. For magnesium
sulphate the shortage appeared to be created by increased
demand.
Therefore, the objective of this descriptive study was
to examine intravenous magnesium use in a large ter-
tiary Canadian hospital over the last 10 years. Further-
more, we sought to determine factors associated with
administration of magnesium in a restricted cohort of
patients during this time period. We hypothesized that
there would be a secular trend to higher use of intraven-
ous magnesium. The primary outcome would be a quan-
tification of use with secondary outcomes of interest to
determine which hospital units, which patients and for
what indications. Additionally we tested the hypothesis




Magnesium sulphate use was determined from phar-
macy records at Capital Health (New Halifax Infirmary
and Victoria General sites). This institution is a tertiary
care center for Nova Scotia (population approximately
960,000) but also provides specialized care for the other
Atlantic Provinces. Since magnesium sulphate is not unit
dosed, floor consumption was estimated from quarterly
use of existing floor stock records. Fiscal year data was
available from 2003 to the last quarter of 2013. The
focus of this analysis was intravenous magnesium use on
the in-hospital medical units (as opposed to operating
rooms, emergency and out-patients clinics) and did not
include magnesium used in parental nutrition solutions.
The units of interest included all intensive care units
(cardiac care unit, cardiac surgery, and two medical-
surgical intensive care units), surgical floors (general (9A
and 9B), urology (5B), surgical oncology (5A), thoracic
(6A), orthopedics (7.2), neurosurgery (7.3), vascular (4.1
and 7.1) medical floors [general (8.2), neurology (8.1),
hematology (8B), cardiology (6.2 and 6.4)] and mixed
floors (6B and 8.3).
Since this institution level data does not identify which
patients received intravenous magnesium and what the
indications were, a detailed chart review of patients from
five floors (cardiology (6.2), cardiac care unit (6.4), generalsurgery (9A and 9B), mixed surgery/nephrology (6B), gen-
eral medicine (8.2 and 8.4)) was also undertaken. These
floors were identified to have considerable increases in
magnesium use over the time period.
Derivation of restricted cohort
All consecutive patients discharged (including death) in
April 2006 and April 2013 were reviewed to eliminate
selection bias. The year 2006 was chosen since this was
the onset of the increase in use of intravenous magne-
sium and this was the year that hospital records were
made electronic. April 2013 was selected as this allowed
6 months of follow up at the time of data collection. Pa-
tients discharged within 24 h, those who had no blood
work during the admission and those who were readmit-
ted within the month were excluded.
Outcome and potential confounders
The primary outcome of the analysis on this restricted
cohort was intravenous magnesium use (yes/no). To
identify factors associated with magnesium use, data was
collected on discharge diagnosis, whether patients were
admitted through emergency, whether their stay in-
cluded time in an intensive care unit, and whether they
received surgery. Information on patient co-morbidity
was collected including ischemic heart disease, congestive
heart failure, atrial fibrillation, chronic kidney disease,
hypertension, diabetes mellitus, liver disease, alcohol
abuse (as defined in the records), cancer and chronic ob-
structive pulmonary disease. Comorbid conditions were
based on documentation through electronic patient re-
cords. All encounters including inpatient and outpatient
were reviewed. Hospital admission laboratory data includ-
ing serum creatinine, potassium, hemoglobin, albumin,
calcium and magnesium was collected. Magnesium, albu-
min, calcium, and potassium levels were also collected at
the time of intravenous magnesium use if available. Esti-
mated glomerular filtration rate (GFR) was measured by
the four variable Modified Diet in Renal Disease (MDRD)
formula [25]. The charts were reviewed to determine if pa-
tients were on oral magnesium, calcineurin inhibitors,
proton pump inhibitors or non-potassium sparing di-
uretics. For patients with a history of cancer the chart was
reviewed to look for evidence of prior cisplatin adminis-
tration. Admission and in-hospital EKG reports were ex-
amined for a diagnosis of arrhythmia (including atrial
fibrillation, ventricular tachycardia or fibrillation, and long
corrected QT interval-as defined by the cardiologist re-
port). In patients receiving intravenous magnesium follow
up blood work was reviewed to determine if serum
magnesium levels had been done after discharge within
a 6-month period. In addition to patient factors, each
patient record was reviewed to determine the indica-
tion for intravenous magnesium administration. Since
Fig. 1 All Intravenous Magnesium Use on Hospital Wards 2003–
2013. Patient Flow for the 2006 Cohort
Fig. 2 Intravenous Magnesium Use on Medical Wards 2003–2013.
Patient Flow for the 2013 Cohort
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intravenous magnesium administration, prior to data
analysis, the authors after a review of the literature
agreed indications should include severely low levels
(magnesium ≤0.5 mmol/L), or a low level (0.5 to
0.74 mmol/L) in patients with long corrected QT or
other arrhythmia, low potassium (≤3.0 mmol/L), low
corrected calcium (≤2.0 mmol/L), neuromuscular prob-
lems or ongoing gastrointestinal loss (diarrhea, vomiting,
post operative ileus or bowel obstruction) [1, 26].
Serum magnesium was measured on the hospital’s
Synchron DxC (Beckman Coulter Inc., CA). The re-
ported normal range is 0.74 to 1.03 mmol/L. The co-
efficient of variation is 3.8 % in plasma. There were no
changes in methodology over the 10-year period. A
corrected magnesium and calcium was calculated if an
albumin level was available. The formulas were as fol-
lows: corrected magnesium [mmol/L] = magnesium
[mmol/L] + 0.005*(40-albumin [g/L]) and corrected
calcium [mmol/L] = Calcium [mmol/L] + 0.025* (40-albu-
min [g/L]) respectively [27, 28].
Statistical analysis
Data for magnesium use in the institution was collected
by fiscal year. Baseline characteristics of patients from
2006 and 2013 were described as means ± standard devi-
ation (SD) for continuous normally distributed variables,
median and interquartile range for non-normally distrib-
uted variables and number and percentage for categorical
variables. Statistical tests of comparison were performed
using independent t-tests, the Rank Sum test and Fisher’s
Exact test, accordingly. Multivariable nested logistic re-
gression models were used to determine if there was an
independent association between era (2013 versus 2006)
and use of intravenous magnesium among those patients
with available magnesium laboratory measurements. Vari-
ables selected for inclusion in the multivariable models
were performed a priori and included demographics, co-
morbidities, medications associated with hypomagnes-
aemia, presence or absence of a low serum magnesium
level at hospital admission, and whether or not there were
indications to give magnesium intravenously based on ra-
tionale outlined above. For all statistical analyses a 2 sided
P value <0.05 was considered statistically significant. All
analyses were performed using Stata IC version 12.0
(StataCorp LP, College Station, TX). Research ethics
approval to conduct this study was obtained from Capital
Health Research Ethics Board.
Results
Magnesium Use at The Hospital Level: Over the last
seven years (2006–2013) of this ten-year review, there
was a 2.86 fold increase in magnesium use on the hos-
pital wards and intensive care units. Figure 1 shows thechange in all, intensive care units, medical and surgical
floors. Despite the increase in use there was variability
between individual units. Hematology (including the
bone marrow unit) was a heavy user of intravenous mag-
nesium, whereas the other medicine floors combined
witnessed a 12.9 fold increase in intravenous magnesium
use (Fig. 2). There was a 6.9 fold increase in intravenous
magnesium use on the surgical wards. The cardiovascu-
lar intensive care unit had a consistently high use
whereas the two medical surgical intensive care units
had a 5.1 fold increase in use (Fig. 3). Over this time
period there was very little variation in the annual num-
ber of hospital cases, length of stay and in hospital mor-
tality (Table 1).
Magnesium Use at the Patient Level in 2006 and 2013
Cohorts: The patient level analysis was consistent with
the findings of an increase in magnesium use. Character-
istics of the 2006 and the 2013 cohorts were similar with
Fig. 3 Intravenous Magnesium Use on Surgical Wards 2003–2013
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values (Table 2).
The average measured magnesium levels were lower in
the 2013 cohort, whereas the frequency of testing, esti-
mated MDRD GFR, use of proton pump inhibitors and
prevalence of atrial fibrillation was higher compared to
2006. Very few patients (<3 %) were admitted on oral
magnesium therapy in either era. Intravenous magne-
sium was administered to 22 of the 397 (5.5 %) patients
and 96 of 371 (25.9 %) patients in the 2006 and 2013 co-
horts respectively. Nearly 41 % (96/233) of 2013 patients
with a magnesium level were given an intravenous dose
in 2013 compared to 12 % (21/173) in 2006. All patients
(12/12) spending time in the medical intensive care unit
in 2013 were given intravenous magnesium compared to
67 % (8/12) in 2006. Excluding patients spending time in
an intensive care unit, intravenous magnesium on medical
and surgical floors increased 6.9 fold. In the fully adjusted
model (Table 3) the odds ratio for intravenous magnesium
use was 13.91 (95 % CI, 6.21-31.17, p < 0.001) for patients
in 2013 compared to 2006.Table 1 Hospital Activity 2003-2013




2003/4 23,768 9.6 1266 5.32
2004/5 24,470 9.51 1348 5.51
2005/6 24,675 9.61 1226 4.97
2006/7 24,016 10.26 1261 5.25
2007/8 24,597 10.28 1225 4.98
2008/9 24,807 9.72 1198 4.83
2009/10 25,489 9.82 1228 4.82
2010/11 25,613 9.65 1231 4.81
2011/12 25,595 9.31 1140 4.45
2012/13 25,299 9.28 1273 5.03In the 2013 cohort, 39 % (37/96) had an indication for
intravenous magnesium. These included ongoing loss
and inability to take oral magnesium (15), EKG abnor-
malities (6), and electrolyte disturbances (16). However
25 % (24/96) had values in the normal range. Albumin
was available in 70 of the 96 patients at the time. Of the
24 patients, 12 had a normal corrected magnesium and
12 had a level within the normal range (uncorrected).
There were also significant differences in magnesium
measured and treated for the same diagnosis. For
example in the 2013 cohort, patients admitted to the
coronary care unit with a myocardial infarction all had
magnesium ordered and 64 % (18/27) received intraven-
ous magnesium. Those admitted with a myocardial infarc-
tion to an alternative level cardiac unit were significantly
less likely to have their magnesium measured (53 %,
16/30, p < 0.001) or receive intravenous magnesium
(13 %, 4/30, p < 0.001).
Of the 96 patients in the 2013 cohort receiving intra-
venous magnesium, 90 had a repeated value at or near
discharge (Table 4). Of these 28 patients (31 %) had a
value that was less than 0.74 mmol/L that was not
treated. Only 3 patients were discharged on oral magne-
sium and 2 of the 3 were on oral magnesium prior to ad-
mission. Only 25 patients had magnesium re-measured
after discharge and of these 17 (68 %) were low with a
mean level of 0.67 mmol/L.Discussion
The principal findings of this analysis are that there has
been a significant increase in intravenous magnesium
use in this hospital on most of the medical and surgical
wards. The administration of intravenous magnesium may
be unnecessary in a significant proportion of patients.
There are no consistent indications for administration,
and treatment behaviors are different among individual
wards. The focus on treating hypomagnesaemia is during
patients’ in-hospital stay. Many of the patients treated for
hypomagnesaemia with intravenous magnesium left hos-
pital with levels that were low or not measured.
This study shows that magnesium administration has
increased over the last 7 years. The reasons behind this
change in practice are independent of blood levels, case
mix and co-morbidity. In patients with a measured mag-
nesium level, blood levels were lower in the more recent
cohort. However this difference might not have been
seen if all patients were tested in 2006. Other unmeas-
ured differences might be responsible for the increase in
magnesium infusions. It is interesting to point out that
proton pump inhibitor use is associated with hypomag-
nesemia [29] and hypomagnesaemia is associated with
atrial fibrillation [30]. All three were more prevalent in
the recent 2013 cohort. However there was no apparent
Table 2 Baseline Characteristics of All Patients from 2006 and 2013
Variable 2006 (N = 397) 2013 (N = 372) P Value
Age 61 ± 17 63 ± 15 0.153
Male Sex n (%) 228 (57) 211 (57) 0.884
Location <0.001
Cardiology 126 (32) 122 (33)
Coronary Care Unit 38 (10) 35 (9)
Medical/Surgical Ward 29 (7) 62 (17)
General Surgery 136 (34) 75 (20)
Internal Medicine 68 (17) 78 (21)
Medical Co-morbidities
Diabetes Mellitus 112 (28) 114 (31) 0.477
Hypertension 221 (56) 214 (58) 0.611
Atrial Fibrillation 41 (10) 69 (19) 0.001
Congestive Heart Failure 63 (16) 53 (14) 0.547
Ischemic Heart Disease 134 (34) 102 (27) 0.061
Chronic Obstructive Lung Disease 55 (14) 61 (16) 0.364
Malignancy 69 (17) 69 (19) 0.707
Liver Disease 19 (5) 24 (6) 0.348
Chronic Kidney Disease 100 (25) 92 (25) 0.934
(GFR < 60 ml/min/1.73 m2)
Alcohol Abuse 8 (2) 14 (4) 0.194
Gastrointestinal Symptoms 83 (21) 102 (27) 0.043
Surgery 96 (24) 87 (23) 0.865
Medications
Calcineurin Inhibitor 9 (2) 13 (3) 0.388
Diuretics 125 (31) 121 (33) 0.758
Proton Pump Inhibitors 100 (25) 130 (35) 0.004
Oral Magnesium 9 (2) 11 (3) 0.652
Laboratory mean (SD)
Calcium (Total) (n = 171/210) 2.17 (2.04-2.30) 2.10 (2.01-2.12) 0.002
Potassium (n = 396/369) 4.1 (3.8-4.5) 4.2 (3.8-4.5) 0.968
Hemoglobin (n = 396/371) 127 (111–143) 127 (108–140) 0.163
Albumin (n = 149/158) 30 (26–34) 30 (24–34) 0.649
MDRD GFR (396/266) 63 (42–81) 69 (45–88) 0.023
Magnesium (N = 173/233) 0.84 (0.75-0.92) 0.78 (0.71-0.86) <0.001
Admission Magnesium Low (n = 173/233) 39 (23) 76 (33) 0.030
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study.
Many of the patients especially those undergoing
bowel surgery were identified to have hypomagnesemia
and appropriately received intravenous magnesium.
However the majority of other treated patients may not
have required intravenous therapy. Correcting abnormal
test results when possible is an easily defensible action
when there is no contrary evidence that treatment wouldcause harm. There is however evidence of harm in the
large trials using intravenous magnesium in patients
with a myocardial infarction. Rates of bradycardia and
hypotension were higher in the treated arms without any
survival benefit [17]. However many of these subjects re-
ceived high rates of infusion and may have developed
hypermagnesemia. Paradoxically ionized hypermagne-
saemia was associated with increased mortality in one
study of patients in an intensive care unit [31]. The usual
Table 3 Association between era (2013 versus 2006) and
administration of intravenous magnesium
Model Odds Ratio [95 % CI] P
Unadjusted 5.07 [3.00-8.58] <0.001
Model 1a 5.09 [3.00-8.62] <0.001
Model 1b 5.60 [3.25-9.66] <0.001
Model 1c 5.60 [3.24-9.67] <0.001
Model 1d 5.98 [3.33-10.74] <0.001
Model 1e 9.24 [4.78-17.87] <0.001
Model 1f 12.89 [6.23-26.68] <0.001
Model 1g 13.91 [6.21-31.17] <0.001
Adjusted for:
aage, gender
bfactors in a) and comorbidities (ischemic heart disease, diabetes, atrial
fibrillation, cancer, heart failure, chronic kidney disease)
cfactors in b) and medications (diuretics, proton pump inhibitors)
dfactors in c) and low admission magnesium
efactors in d) and admission ward location (cardiology, coronary care unit,
medicine ward, surgical ward mixed medicine/surgery ward)
ffactors in e) and cardiac indication for intravenous magnesium
gfactors in e) and cardiac or other indication for intravenous magnesium
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administered over 1 h would transiently increase the
magnesium levels to a hypermagnesemic state assuming
the extracellular volume of distribution is 10–16 l of
water.
There does not appear to be any evidence-based
guidelines that inform indications for magnesium meas-
urement. For example despite the evidence that hypo-
magnesemia is associated with atrial fibrillation and is
useful to prevent post cardiac surgery atrial fibrillation,
Canadian and US guidelines do not specifically recom-
mend assessment of magnesium in the initial evaluation
of atrial fibrillation [32, 33]. In addition the recommen-
dations for treatment of deficiency are opinion based.Table 4 Follow up Magnesium Levels in Treated Patients: 2013
Cohort
Variable Intravenous Magnesium
Given (N = 96)
Discharge Magnesium Persistently
Low (N = 90)
28 (31 %)
Magnesium Low After Discharge (N = 25) 17 (68 %)




Magnesium Level After Discharge mmol/L 0.67 (0.46-0.92)
>0.74 8
0.50-0.74 15
<0.50 2For these reasons practice is likely to vary considerably
within and between institutions. Some general medicine
reference sites recommend treatment of asymptomatic
hospitalized patients with intravenous magnesium for
levels just below the normal range [26]. There seems to
be less emphasis on oral replacement. Magnesium is an
excellent laxative and may not be tolerated by many pa-
tients. However the increased intensity of measuring and
treating hypomagnesaemia in hospitalized patients over
the last 7 years has not been matched by treatment in
outpatients. The medical aspects of low dietary magne-
sium intake and low serum levels in community popula-
tions have been studied extensively over the years [6–9].
Some but not all studies support magnesium supple-
mentation or increased intake for blood pressure con-
trol, dyslipidemia, glucose metabolism, stroke prevention
and dysrhythmia prevention [2, 6–12]. Oral magnesium
supplementation in patients entering hospital is rela-
tively low in our study and was not different between
the 2006 and 2013 cohorts. If treatment of low magne-
sium is important, more attention is needed in the out-
patient services.
This analysis may reflect a trend in health care, this
being a desire to identify and aggressively treat many
facets of an individual’s physiology while in hospital.
This adds to the complexity and costs of care and may
not result in any short or long term benefit. Intravenous
magnesium is relatively inexpensive but the nursing and
pharmacy time costs to administer the medication may
be much higher.
There are several limitations to this study. This study
was unable to determine whether intravenous supple-
mentation would reduce in hospital mortality. A large
randomized control trial would be necessary. We did
not systematically examine all patients over the 10-year
time period. However it is not clear a larger study would
change the conclusions of this report, given the findings
of the institutional analysis. It would also be interesting
to know if this is a pattern seen in other centers in
North America. The Federal Drug Administration web-
site as of July 2014 continues to identify a shortage of
intravenous magnesium sulphate from increased de-
mand [34]. To date shortages in Canada have not been
as acute [35]. With increasing demand, shortages in
Canada might develop. Finally, while this study identifies
an increase in administration of intravenous magnesium,
the reason behind this increase is not clear. The increase
appears to have happened in most units after 2006. Only
a few units have pre-printed orders for the measurement
of magnesium or the treatment of hypomagnesaemia.
There does not appear to be any groundbreaking studies
in the last 6 years to explain this change in administra-
tion of intravenous magnesium, except possibly in treat-
ment of acute asthma [19].
Kiberd et al. Canadian Journal of Kidney Health and Disease  (2015) 2:24 Page 8 of 8Conclusion
The measurement of serum magnesium and the use of
intravenous magnesium in this tertiary care center have
increased significantly. The reasons for this change in
practice are unclear. More research is needed to deter-
mine whether this change in practice has any benefit on
patient outcomes.
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